FibroBiologics Files 8K - Entry Into Definitive Agreement >FBLG

FibroBiologics Inc. (FBLG) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on October 08, 2026. On October 7, 2026, FibroBiologics, Inc. (the "Company") entered into a securities purchase agreement (the "SPA") with Peak One Opportunity Fund, L.P. ("Peak One"), pursuant to which the Company agreed to issue to Peak One, in a private placement offering (the "Offering") upon the satisfaction of certain conditions specified in the SPA, a convertible debenture in the principal amount of $1,200,000 (the "Debenture") and 125,000 restricted shares (the "Commitment Shares") of the Company's common stock, par value $0.00001 per share (the "common stock"). The Offering closed on October 8, 2026, and the Company issued the Debenture to Peak One and the Commitment Shares to Peak One and Peak One's designee as described in the SPA. The Debenture was sold to Peak One for a purchase price of $1,020,000, representing an original issue discount of fifteen percent (15%). In connection with the offering, the Company paid $20,000 as a non-accountable fee to Peak One to cover its.